EGFR TKIs Suppress MUC1 Glycosylation through the PI3K/AKT/SP1/C1GALT1 Pathway to Enhance TnMUC1 CAR-T Efficacy in EGFR-Mutant NSCLC

Investigators showed that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) enhance the efficacy of TnMUC1 CAR-T cell therapy in EGFR-mutant NSCLC, both in vitro and in vivo.